J&J And Sanofi Team Up On Phase III E. Coli Vaccine
Executive Summary
Sanofi will pay $175m up front for rights to commercialize J&J’s potential first-in-class vaccine against E. coli. The two companies will share profits.
You may also be interested in...
Sanofi Eyes External Deals On Top Of Promising Pipeline
The French drugmaker is significantly upping its investments in R&D but recent major deals with J&J and Teva show that Sanofi is still open to expanding its external programs as well.
Deal Watch: Bayer Ties Up With Twist On Optimization Of Antibody Discovery
Plus deals involving Advanz/Dimerix, Boehringer Ingelheim/Zeiss Medical Technology, Roche/Ionis, Kriya/Everads and updates from the world of technology transfer.
Several Options Remain For Cidara’s Flu Candidate After J&J Halts Development
Clinical work on the US biotech’s drug-Fc conjugate, CD388, has been stopped by partner Janssen amid a broader company shift, but there are several paths forward for Cidara after the asset showed early promise in a Phase IIa trial.